Compare JQC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JQC | ENGN |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 647.1M |
| IPO Year | N/A | N/A |
| Metric | JQC | ENGN |
|---|---|---|
| Price | $4.73 | $6.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 906.0K | 527.5K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.60 | $2.66 |
| 52 Week High | $5.58 | $12.25 |
| Indicator | JQC | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 37.27 |
| Support Level | $4.69 | $6.60 |
| Resistance Level | $5.14 | $7.33 |
| Average True Range (ATR) | 0.08 | 0.52 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 39.29 | 34.22 |
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.